Moleculin Biotech
MBRX
22 hedge funds and large institutions have $2.04M invested in Moleculin Biotech in 2020 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 2 closing their positions.
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
22% more funds holding
Funds holding: 18 → 22 (+4)
0% less ownership
Funds ownership: 0% → 0% (-0%)
11% less capital invested
Capital invested by funds: $2.28M → $2.04M (-$241K)
60% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$46.1K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$44.4K |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
+$21.3K |
| 4 |
HF
HRT Financial
New York
|
+$8.87K |
| 5 |
Squarepoint
New York
|
+$8.87K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$179K |
| 2 |
Wells Fargo
San Francisco,
California
|
-$65.7K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$26.6K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$21.3K |
| 5 |
Barclays
London,
United Kingdom
|
-$5.32K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Millennium Management
New York
| – | -$171 | -93 | Closed |
|
|
27
Wells Fargo
San Francisco,
California
| – | -$65.7K | -37 | Closed |
|
|
PFO
28
Pathstone Family Office
Englewood,
New Jersey
| – | -$1K | – | – |
|
MBRX Hedge Fund Activity: Q4 2020 in Review
22 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q4 2020, worth a combined $2.04M — down 11% from $2.28M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new MBRX positions and 2 closed out — a net gain of 5 holders — while 2 added to existing stakes and 5 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $46.1K. The largest seller was Qube Research & Technologies (QRT), cutting an estimated $179K.
- 22 institutional investors held Moleculin Biotech (MBRX) as of Q4 2020, up from 18 in Q3 2020.
- Funds reported $2.04M of Moleculin Biotech stock for Q4 2020, down 11% quarter-over-quarter.
- 7 funds opened new Moleculin Biotech positions in Q4 2020 and 2 closed out, a net change of +5 holders.
- The largest Moleculin Biotech buyer in Q4 2020 was Renaissance Technologies, an estimated $46.1K added.
- The largest Moleculin Biotech seller in Q4 2020 was Qube Research & Technologies (QRT), an estimated $179K sold.
Based on aggregated 13F filings for Q4 2020.